Retinal toxicities of cancer therapy drugs: Biologics, small molecule inhibitors, and chemotherapies

Catherine Y. Liu, Jasmine H. Francis, Scott E. Brodie, Brian Marr, Jose S Pulido, Michael F. Marmor, David H. Abramson

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

PURPOSE: To review reported retinal side effects from current cancer therapy drugs. METHODS: Retinal toxicities from ophthalmologic or oncologic case reports, case series, and clinical trials were identified by a systematic literature search using Lexicomp and PubMed. RESULTS: Four biologics, 8 small molecule inhibitors, and 17 traditional chemotherapy agents had reported retinal side effects. For biologics, interferon alpha 2b was associated with retinopathy, denileukin diftitiox with pigmentary retinopathy, ipilimumab with a Vogt-Koyanagi-Harada-like syndrome, and trastuzumab with retinal ischemia. For small molecule inhibitors, v-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors were associated with uveitis, mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitors with pigment epithelium detachments, and tyrosine kinase inhibitors with macular edema. Steroid antagonists were associated with crystalline retinopathy and macular edema. Nitrosoureas, platinum analogs, and cytosine arabinoside were associated with retinal vascular occlusions. Antimicrotubular agents were associated with cystoid macular edema but without fluorescein leakage. Retinoic acid derivatives were associated with impaired night vision, and mitotane was associated with a pigmentary retinopathy and papilledema. CONCLUSION: Certain agents used in the treatment of systemic cancer are associated with ocular complications. Awareness of these complications will allow early detections and maybe reversal of some of the ocular problems.

Original languageEnglish (US)
Pages (from-to)1261-1280
Number of pages20
JournalRetina
Volume34
Issue number7
DOIs
StatePublished - 2014

Fingerprint

Retinal Neoplasms
Biological Therapy
Macular Edema
Retinitis Pigmentosa
interferon alfa-2b
Biological Products
Drug Therapy
Mitotane
Night Vision
Uveomeningoencephalitic Syndrome
Retinal Vessels
Papilledema
Second Primary Neoplasms
Cytarabine
Uveitis
Extracellular Signal-Regulated MAP Kinases
Tretinoin
Mitogen-Activated Protein Kinases
Platinum
Fluorescein

Keywords

  • cancer
  • chemotherapy
  • drug toxicity
  • monoclonal antibody
  • retina
  • retinal toxicities
  • side effects
  • tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Ophthalmology
  • Medicine(all)

Cite this

Liu, C. Y., Francis, J. H., Brodie, S. E., Marr, B., Pulido, J. S., Marmor, M. F., & Abramson, D. H. (2014). Retinal toxicities of cancer therapy drugs: Biologics, small molecule inhibitors, and chemotherapies. Retina, 34(7), 1261-1280. https://doi.org/10.1097/IAE.0000000000000242

Retinal toxicities of cancer therapy drugs : Biologics, small molecule inhibitors, and chemotherapies. / Liu, Catherine Y.; Francis, Jasmine H.; Brodie, Scott E.; Marr, Brian; Pulido, Jose S; Marmor, Michael F.; Abramson, David H.

In: Retina, Vol. 34, No. 7, 2014, p. 1261-1280.

Research output: Contribution to journalArticle

Liu, CY, Francis, JH, Brodie, SE, Marr, B, Pulido, JS, Marmor, MF & Abramson, DH 2014, 'Retinal toxicities of cancer therapy drugs: Biologics, small molecule inhibitors, and chemotherapies', Retina, vol. 34, no. 7, pp. 1261-1280. https://doi.org/10.1097/IAE.0000000000000242
Liu, Catherine Y. ; Francis, Jasmine H. ; Brodie, Scott E. ; Marr, Brian ; Pulido, Jose S ; Marmor, Michael F. ; Abramson, David H. / Retinal toxicities of cancer therapy drugs : Biologics, small molecule inhibitors, and chemotherapies. In: Retina. 2014 ; Vol. 34, No. 7. pp. 1261-1280.
@article{87cd560cde9b47e298436fdd8362c139,
title = "Retinal toxicities of cancer therapy drugs: Biologics, small molecule inhibitors, and chemotherapies",
abstract = "PURPOSE: To review reported retinal side effects from current cancer therapy drugs. METHODS: Retinal toxicities from ophthalmologic or oncologic case reports, case series, and clinical trials were identified by a systematic literature search using Lexicomp and PubMed. RESULTS: Four biologics, 8 small molecule inhibitors, and 17 traditional chemotherapy agents had reported retinal side effects. For biologics, interferon alpha 2b was associated with retinopathy, denileukin diftitiox with pigmentary retinopathy, ipilimumab with a Vogt-Koyanagi-Harada-like syndrome, and trastuzumab with retinal ischemia. For small molecule inhibitors, v-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors were associated with uveitis, mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitors with pigment epithelium detachments, and tyrosine kinase inhibitors with macular edema. Steroid antagonists were associated with crystalline retinopathy and macular edema. Nitrosoureas, platinum analogs, and cytosine arabinoside were associated with retinal vascular occlusions. Antimicrotubular agents were associated with cystoid macular edema but without fluorescein leakage. Retinoic acid derivatives were associated with impaired night vision, and mitotane was associated with a pigmentary retinopathy and papilledema. CONCLUSION: Certain agents used in the treatment of systemic cancer are associated with ocular complications. Awareness of these complications will allow early detections and maybe reversal of some of the ocular problems.",
keywords = "cancer, chemotherapy, drug toxicity, monoclonal antibody, retina, retinal toxicities, side effects, tyrosine kinase inhibitors",
author = "Liu, {Catherine Y.} and Francis, {Jasmine H.} and Brodie, {Scott E.} and Brian Marr and Pulido, {Jose S} and Marmor, {Michael F.} and Abramson, {David H.}",
year = "2014",
doi = "10.1097/IAE.0000000000000242",
language = "English (US)",
volume = "34",
pages = "1261--1280",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Retinal toxicities of cancer therapy drugs

T2 - Biologics, small molecule inhibitors, and chemotherapies

AU - Liu, Catherine Y.

AU - Francis, Jasmine H.

AU - Brodie, Scott E.

AU - Marr, Brian

AU - Pulido, Jose S

AU - Marmor, Michael F.

AU - Abramson, David H.

PY - 2014

Y1 - 2014

N2 - PURPOSE: To review reported retinal side effects from current cancer therapy drugs. METHODS: Retinal toxicities from ophthalmologic or oncologic case reports, case series, and clinical trials were identified by a systematic literature search using Lexicomp and PubMed. RESULTS: Four biologics, 8 small molecule inhibitors, and 17 traditional chemotherapy agents had reported retinal side effects. For biologics, interferon alpha 2b was associated with retinopathy, denileukin diftitiox with pigmentary retinopathy, ipilimumab with a Vogt-Koyanagi-Harada-like syndrome, and trastuzumab with retinal ischemia. For small molecule inhibitors, v-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors were associated with uveitis, mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitors with pigment epithelium detachments, and tyrosine kinase inhibitors with macular edema. Steroid antagonists were associated with crystalline retinopathy and macular edema. Nitrosoureas, platinum analogs, and cytosine arabinoside were associated with retinal vascular occlusions. Antimicrotubular agents were associated with cystoid macular edema but without fluorescein leakage. Retinoic acid derivatives were associated with impaired night vision, and mitotane was associated with a pigmentary retinopathy and papilledema. CONCLUSION: Certain agents used in the treatment of systemic cancer are associated with ocular complications. Awareness of these complications will allow early detections and maybe reversal of some of the ocular problems.

AB - PURPOSE: To review reported retinal side effects from current cancer therapy drugs. METHODS: Retinal toxicities from ophthalmologic or oncologic case reports, case series, and clinical trials were identified by a systematic literature search using Lexicomp and PubMed. RESULTS: Four biologics, 8 small molecule inhibitors, and 17 traditional chemotherapy agents had reported retinal side effects. For biologics, interferon alpha 2b was associated with retinopathy, denileukin diftitiox with pigmentary retinopathy, ipilimumab with a Vogt-Koyanagi-Harada-like syndrome, and trastuzumab with retinal ischemia. For small molecule inhibitors, v-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors were associated with uveitis, mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitors with pigment epithelium detachments, and tyrosine kinase inhibitors with macular edema. Steroid antagonists were associated with crystalline retinopathy and macular edema. Nitrosoureas, platinum analogs, and cytosine arabinoside were associated with retinal vascular occlusions. Antimicrotubular agents were associated with cystoid macular edema but without fluorescein leakage. Retinoic acid derivatives were associated with impaired night vision, and mitotane was associated with a pigmentary retinopathy and papilledema. CONCLUSION: Certain agents used in the treatment of systemic cancer are associated with ocular complications. Awareness of these complications will allow early detections and maybe reversal of some of the ocular problems.

KW - cancer

KW - chemotherapy

KW - drug toxicity

KW - monoclonal antibody

KW - retina

KW - retinal toxicities

KW - side effects

KW - tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84903136232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903136232&partnerID=8YFLogxK

U2 - 10.1097/IAE.0000000000000242

DO - 10.1097/IAE.0000000000000242

M3 - Article

C2 - 24949716

AN - SCOPUS:84903136232

VL - 34

SP - 1261

EP - 1280

JO - Retina

JF - Retina

SN - 0275-004X

IS - 7

ER -